8-K: Simulations Plus Reports Q4, FY25 Results; Reaffirms 2026 Guidance

Simulations Plus reported a 6% revenue decrease in Q4 2025 and a significant full-year net loss of $64.7 million due to an impairment charge, while reaffirming fiscal 2026 revenue guidance.

Summary

• Fourth quarter 2025 total revenue decreased 6% to $17.5 million compared to the fourth quarter of 2024.
• Fourth quarter 2025 software revenue decreased 9% to $9.0 million, representing 52% of total revenue.
• Fourth quarter 2025 services revenue decreased 3% to $8.4 million, representing 48% of total revenue.
• Fourth quarter 2025 net loss was $0.7 million, resulting in a diluted loss per share of $0.03.
• Full year 2025 total revenue increased 13% to $79.2 million compared to full year 2024.
• Full year 2025 software revenue increased 12% to $45.8 million, representing 58% of total revenue.
• Full year 2025 services revenue increased 15% to $33.4 million, representing 42% of total revenue.
• Full year 2025 net loss was $64.7 million, with a diluted loss per share of $3.22, which includes a non-cash impairment charge of $77.2 million.
• Reaffirmed fiscal year 2026 total revenue guidance of $79 million to $82 million, representing 0-4% growth.
• Reaffirmed fiscal year 2026 adjusted diluted EPS guidance of $1.03 to $1.10.

Sentiment

Score: 4

Explanation: While the company met its revised fiscal 2025 guidance for adjusted metrics and is strategically positioning itself in AI and cloud solutions, the substantial GAAP net loss for the full year due to a large impairment charge and the revenue decline in the fourth quarter are significant concerns. The reaffirmed 2026 guidance indicates only low single-digit growth in a cautious demand environment.

Positives

• Successfully met revised fiscal 2025 guidance for adjusted metrics.
• Full year 2025 total revenue increased 13% to $79.2 million.
• Full year 2025 adjusted EBITDA grew 8% to $22.0 million.
• Full year 2025 adjusted diluted EPS grew 8% to $1.03.
• Services backlog stands at $18.0 million, with over 91% expected to convert to revenue within 12 months.
• Strategic focus on launching an ambitious product vision that links validated modeling engines with cloud-scale compute, AI-assisted workflows, and a stronger compliance and identity framework.

Negatives

• Fourth quarter 2025 total revenue decreased 6% to $17.5 million.
• Fourth quarter 2025 software revenue decreased 9% and services revenue decreased 3%.
• Fourth quarter 2025 net loss of $0.7 million and diluted loss per share of $0.03.
• Full year 2025 net loss of $64.7 million and diluted loss per share of $3.22, primarily due to a $77.2 million non-cash impairment charge.
• Adjusted EBITDA margin decreased to 20% in Q4 2025 from 22% in Q4 2024, and to 28% in FY25 from 29% in FY24.
• The demand environment remains cautious.
• Software renewal rates were impacted by client consolidations and site closures.

Risks

• Effectiveness of the new internal operational structure.
• Ability to maintain competitive advantages and commercialize AI and cloud-enabled solutions.
• Evolving regulatory and data privacy standards governing AI technologies.
• Acceptance of new software and improved versions of existing software by customers.
• General economics of the pharmaceutical industry.
• Ability to finance growth.
• Ability to continue to attract and retain highly qualified technical staff.
• Market conditions and macroeconomic factors.
• A sustainable market.

Future Outlook

Simulations Plus reaffirms its fiscal year 2026 guidance, anticipating total revenue between $79 million and $82 million (0-4% growth) and adjusted diluted EPS between $1.03 and $1.10. The company expects low single-digit revenue growth assuming current cautious market conditions persist but believes it is well-positioned for upside if the spending environment improves. A new product vision focusing on cloud deployment, AI-assisted workflows, and enhanced compliance is being launched to cut cycle times, increase cross-product adoption, and open new enterprise opportunities.

Management Comments

• "By successfully meeting our revised fiscal 2025 guidance, we have demonstrated Simulations Plus resilience and agility in navigating evolving market dynamics." Shawn O'Connor, CEO.
• "We delivered 13% revenue growth and achieved 8% growth in both adjusted EBITDA and adjusted EPS." Shawn O'Connor, CEO.
• "Looking ahead to fiscal 2026, we anticipate low single-digit revenue growth at the mid-point of the guidance range, assuming current market conditions remain." Shawn O'Connor, CEO.
• "Importantly, we believe we are well-positioned to capture upside should the spending environment improve for our pharmaceutical and biotech clients." Shawn O'Connor, CEO.
• "The demand environment remains cautious, but we believe adoption of cloud deployment, interoperability, and AI-driven workflows is accelerating across our customer base." Shawn O'Connor, CEO.
• "With validated science at the core of every product, we believe Simulations Plus is well positioned to lead the next chapter of AI-enabled drug development." Shawn O'Connor, CEO.

Industry Context

The biopharma sector is increasingly adopting advanced technologies like AI/ML and cloud-based solutions to accelerate drug discovery and development. Simulations Plus's strategic focus on integrating AI-driven workflows, cloud-scale compute, and enhanced compliance frameworks aligns with these industry trends, aiming to improve efficiency and data management for pharmaceutical and biotech clients facing cautious spending environments.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Stakeholder Impact

• Shareholders: Experienced a significant diluted loss per share of $3.22 for FY25 due to a large impairment charge, impacting equity value. The cautious outlook for FY26 suggests limited near-term growth.
• Customers: Facing a cautious demand environment, but are accelerating adoption of cloud deployment, interoperability, and AI-driven workflows, which the company is addressing with new product vision.
• Employees: The non-GAAP adjustments mention "reorganization expense," indicating potential internal restructuring.

Next Steps

• Shawn O'Connor (CEO) and Will Frederick (EVP & CFO) hosted a conference call and webcast on December 1, 2025, at 5:00 p.m. Eastern Time to discuss the results and forward-looking information.
• Simulations Plus will hold a Virtual Investor Day on Wednesday, January 21, 2026, to present its new product vision and AI solutions.

Key Dates

Recommendation

While Simulations Plus achieved its revised fiscal 2025 adjusted guidance and is strategically investing in AI and cloud solutions, the substantial GAAP net loss for the full year, driven by a $77.2 million impairment charge, and the Q4 revenue decline are significant concerns. The reaffirmed fiscal 2026 guidance projects only low single-digit revenue growth, reflecting a cautious market. Investors should hold to monitor the execution of the new product vision and the impact of AI solutions on future revenue growth and profitability, especially given the current demand environment. A 'buy' would be premature given the recent performance and cautious outlook, and a 'sell' might be an overreaction if the strategic shift proves successful.

Keywords

Simulations Plus, SLP, financial results, Q4 2025, fiscal 2025, revenue, net loss, adjusted EPS, guidance, biopharma, biosimulation, cheminformatics, AI solutions, drug development, software, services, impairment charge, investor day